Predictors of gastrointestinal complaints in patients on metformin therapy

• Published in: Open medicine (Warsaw, Poland) Poland), 2023-11, Vol.18 (1), p.20230871-20230871
• Main Authors: Raičević, Branislava, Janković, Slobodan
• Format: Article
• Language: English
• Subjects: Abdomen; anaemia; Anemia; Antidiabetics; Diabetes; Drug stores; metformin intolerance; Nausea; Patients; Pharmacy; Questionnaires; Regression analysis; Risk factors; statins
• ISSN: 2391-5463; 2391-5463
• DOI: 10.1515/med-2023-0871

Although being very effective in the treatment of diabetes and a few other conditions, metformin (MTF) cannot be tolerated by many patients due to gastrointestinal (GI) complaints. A number of risk factors for intolerance were identified, but many are still controversial or uninvestigated. The aim of this study was to further investigate possible risk factors for the occurrence of GI complaints in patients on MTF therapy. A cross-sectional design was used for this multicentric study on adult patients visiting 50 community pharmacies in Montenegro. The patients were surveyed by semi-structured questionnaire after a service of a pharmacist was delivered, and their drugs dispensed. Uni- and multi-variate regression methods were used for processing the data. In total 330 patients participated in the study. A higher body mass index (OR = 1.113, p = 0.003), living at a higher altitude (OR = 1.725, p = 0.000), anaemia (OR = 4.221, p = 0.008), and intestinal infection in the last 3 months (OR = 2.801, p = 0.006) increased the risk of GI complaints in patients on MTF therapy, while the use of statins was protective (OR = 0.204, p = 0.016). Each case of MTF intolerance should be carefully investigated for risk and protective factors, which could be potentially eliminated or augmented, respectively, and MTF withdrawal avoided.